SCHEMBL5378439

SCHEMBL5378439

CCN(CCO)c1ccc(Nc2nc(N3C[C@H](N)C[C@H](N)C3)nc(N3C[C@H](N)C[C@H](N)C3)n2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GBA1 P04062 5/20 0.38
RAD52 P43351 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
NPY5R Q15761 1/20 0.37
SYK P43405 1/20 0.37
PTGS2 P35354 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5375715 0.91 LMNA (0.44) SMN1; SMN2LMNAMAPTALDH1A1HTT
SCHEMBL14503019 0.82 PTGS2 (0.55) SMN1; SMN2LMNAMAPTALDH1A1HTT
SCHEMBL5391020 0.81 LMNA (0.37) SMN1; SMN2LMNAMAPTALDH1A1RAD52
SCHEMBL5426726 0.77 PTGS2 (0.38) SMN1; SMN2LMNAHTTBLMSYK
SCHEMBL5376474 0.77 RAD52 (0.44) SMN1; SMN2LMNAMAPTHTTGBA1
SCHEMBL14428525 0.76 LMNA (0.58) SMN1; SMN2LMNAMAPTHTTGBA1
SCHEMBL5392801 0.76 LMNA (0.43) SMN1; SMN2LMNAMAPTHTTGBA1
SCHEMBL5376174 0.76 RAD52 (0.57) SMN1; SMN2LMNAMAPTRAD52RECQL
SCHEMBL5383801 0.75 MAPT (0.39) SMN1; SMN2LMNAMAPTALDH1A1HTT
SCHEMBL5420671 0.75 LMNA (0.44) SMN1; SMN2LMNAMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-08-23 US disclosed
US-7223759-B2 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds ANADYS PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20050239827-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds ANADYS PHARMACEUTICALS, INC. 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197533-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds DDC, DPP3, AMPD3 SMN1; SMN2 3797/4885LMNA 4065/4885MAPT 2536/4885
US-20050239827-A1 Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds AMPD3, AAAS, PEPD SMN1; SMN2 4041/4885LMNA 4008/4885MAPT 2630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.